Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has released its financial results for the first half of 2026, showing revenue growth and a strategic expansion of its U.S. clinical manufacturing operations. The company, which combines therapeutic development with a revenue-generating contract development and manufacturing organization (CDMO), reported first-half revenue of $949,000, up from $773,000 in the same period last year. More notably, committed customer orders reached approximately $3.1 million as of Aug. 16, 2026, including about $2.1 million already invoiced.
Central to Scinai's growth is its CDMO business, which is now supporting an expanded clinical manufacturing and chemistry, manufacturing, and controls (CMC) program for a U.S.-based biopharmaceutical company. The company has received approximately $650,000 in cash payments and advances for this program, with substantive activities already underway. Although a definitive agreement is still under negotiation, the program is intended to support an investigational drug product toward a U.S. investigational new drug (IND) submission and Phase III clinical development. This initiative underscores Scinai's commitment to strengthening its position in the CDMO market, with the company continuing to pursue approximately $5 million in CDMO revenue for 2026.
Financially, Scinai reported an operating loss of approximately $4.6 million for the first half, compared with $3.8 million in the prior-year period. However, net income was approximately $1.6 million, a significant improvement from a net loss of $4.1 million a year earlier. This swing was primarily driven by a $6.4 million bargain purchase gain associated with the acquisition of Recipharm Israel. As of June 30, 2026, the company held cash, cash equivalents, and restricted cash totaling approximately $2.9 million.
Beyond its CDMO activities, Scinai continues to advance its PC111 and NanoAbs therapeutic programs, which are focused on innovative immunology therapies. The company plans to host an investor webinar on Aug. 26, 2026, to discuss recent developments, financial performance, and upcoming milestones.
Scinai Immunotherapeutics is a biopharmaceutical company that develops therapies licensed from the Max Planck Society and PinCell S.r.l. Its CDMO subsidiary, Scinai Biopharma Services Ltd., provides development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel. The company's recent progress highlights its dual strategy of advancing proprietary therapies while generating revenue through its CDMO services.
